Literature DB >> 19653342

Association of Fas/Apo1 gene promoter (-670 A/G) polymorphism in Tunisian patients with IBD.

Walid Ben Aleya1, Imen Sfar, Leila Mouelhi, Houda Aouadi, Mouna Makhlouf, Salwa Ayed-Jendoubi, Samira Matri, Azza Filali, Taoufik Najjar, Taeib Ben Abdallah, Khaled Ayed, Yousr Gorgi.   

Abstract

AIM: To detect a possible association between the polymorphism of the (-670 A/G) Fas/Apo1 gene promoter and susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) in the Tunisian population.
METHODS: The (-670 A/G) Fas polymorphism was analyzed in 105 patients with CD, 59 patients with UC, and 100 controls using the polymerase chain reaction restriction fragment length polymorphism method.
RESULTS: Significantly lower frequencies of the Fas -670 A allele and A/A homozygous individuals were observed in CD and UC patients when compared with controls. Analysis of (-670 A/G) Fas polymorphism with respect to sex in CD and UC showed a significant difference in A/A genotypes between female patients and controls (P corrected = 0.004 in CD patients and P corrected = 0.02 in UC patients, respectively). Analysis also showed a statistically significant association between genotype AA of the (-670 A/G) polymorphism and the ileum localization of the lesions (P corrected = 0.048) and between genotype GG and the colon localization (P corrected = 0.009). The analysis of inflammatory bowel disease patients according to clinical behavior revealed no difference.
CONCLUSION: Fas-670 polymorphism was associated with the development of CD and UC in the Tunisian population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653342      PMCID: PMC2721238          DOI: 10.3748/wjg.15.3643

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

Review 1.  Fas ligand-induced apoptosis.

Authors:  S Nagata
Journal:  Annu Rev Genet       Date:  1999       Impact factor: 16.830

2.  A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Authors:  C Gasche; J Scholmerich; J Brynskov; G D'Haens; S B Hanauer; E J Irvine; D P Jewell; D Rachmilewitz; D B Sachar; W J Sandborn; L R Sutherland
Journal:  Inflamm Bowel Dis       Date:  2000-02       Impact factor: 5.325

3.  Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci.

Authors:  J D Rioux; M S Silverberg; M J Daly; A H Steinhart; R S McLeod; A M Griffiths; T Green; T S Brettin; V Stone; S B Bull; A Bitton; C N Williams; G R Greenberg; Z Cohen; E S Lander; T J Hudson; K A Siminovitch
Journal:  Am J Hum Genet       Date:  2000-04-21       Impact factor: 11.025

4.  Complete molecular scanning of the human Fas gene: mutational analysis and linkage studies in families with type I diabetes mellitus. The Danish Study Group of Diabetes in Childhood and The Danish IDDM Epidemiology and Genetics Group.

Authors:  R L Nolsøe; O P Kristiansen; K Sangthongpitag; Z M Larsen; J Johannesen; A E Karlsen; F Pociot; J Nerup; C F Verge; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2000-06       Impact factor: 10.122

5.  Linkage of inflammatory bowel disease to human chromosome 6p.

Authors:  J Hampe; S H Shaw; R Saiz; N Leysens; A Lantermann; S Mascheretti; N J Lynch; A J MacPherson; S Bridger; S van Deventer; P Stokkers; P Morin; M M Mirza; A Forbes; J E Lennard-Jones; C G Mathew; M E Curran; S Schreiber
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

6.  IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs.

Authors:  S Fiorucci; L Santucci; G Cirino; A Mencarelli; L Familiari; P D Soldato; A Morelli
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

7.  Risk factors for inflammatory bowel disease in the general population.

Authors:  L A García Rodríguez; A González-Pérez; S Johansson; M-A Wallander
Journal:  Aliment Pharmacol Ther       Date:  2005-08-15       Impact factor: 8.171

Review 8.  The epidemiology and the pathogenesis of inflammatory bowel disease.

Authors:  K Karlinger; T Györke; E Makö; A Mester; Z Tarján
Journal:  Eur J Radiol       Date:  2000-09       Impact factor: 3.528

9.  Evaluation of the apo-1/Fas promoter mva I polymorphism in multiple sclerosis.

Authors:  Q R Huang; S M Teutsch; M M Buhler; B H Bennetts; R N Heard; N Manolios; G J Stewart
Journal:  Mult Scler       Date:  2000-02       Impact factor: 6.312

10.  Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome.

Authors:  A I Bolstad; A Wargelius; B Nakken; H J Haga; R Jonsson
Journal:  J Rheumatol       Date:  2000-10       Impact factor: 4.666

View more
  4 in total

1.  The role of FAS gene variants in inflammatory bowel disease.

Authors:  Ayhan Demir; Resul Kahraman; Gonca Candan; Arzu Ergen
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

2.  Soluble fas and the -670 polymorphism of fas in lupus nephritis.

Authors:  Juan José Bollain-Y-Goytia; Mariela Arellano-Rodríguez; Felipe de Jesús Torres-Del-Muro; Leonel Daza-Benítez; José Francisco Muñoz-Valle; Esperanza Avalos-Díaz; Rafael Herrera-Esparza
Journal:  Int J Nephrol       Date:  2014-11-18

3.  Identification of Candidate Genes Related to Inflammatory Bowel Disease Using Minimum Redundancy Maximum Relevance, Incremental Feature Selection, and the Shortest-Path Approach.

Authors:  Fei Yuan; Yu-Hang Zhang; Xiang-Yin Kong; Yu-Dong Cai
Journal:  Biomed Res Int       Date:  2017-02-14       Impact factor: 3.411

4.  Association of TNF-α -857 Polymorphism with Inflammatory Bowel Disease in a Group of Iranian Azeri Individuals.

Authors:  Haniyeh Rahbar Kafshboran; Mortaza Bonyadi; Hamidreza Miri; Mehdi Haghi; Abbas Nikravesh; Reza Abdolmohammadi; Mohammad Hossein Somi; Manouchehr Khoshbaten
Journal:  Middle East J Dig Dis       Date:  2014-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.